ZimVie to be acquired by ARCHIMED in $730 million deal

PALM BEACH GARDENS - Dental implant market leader ZimVie Inc. (NASDAQ:ZIMV), currently valued at $236 million with a robust 65% gross profit margin, announced Monday it has entered into a definitive agreement to be acquired by healthcare investment firm ARCHIMED in an all-cash transaction valued at approximately $730 million. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.14.

Under the terms of the agreement, ZimVie stockholders will receive $19.00 in cash per share, representing a 99% premium to the company’s 90-day volume-weighted average price of $9.57. The offer comes as ZimVie trades near its 52-week low of $8.15, with InvestingPro analysis showing notably volatile stock price movements throughout the year.

"This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years," said Vafa Jamali, Chairman and CEO of ZimVie.

The transaction, unanimously approved by ZimVie’s Board of Directors, is expected to close by year-end 2025, subject to stockholder approval and regulatory clearances. Upon completion, ZimVie will become a privately held company and its shares will no longer trade on the NASDAQ.

The merger agreement includes a 40-day "go-shop" period through August 29, 2025, during which ZimVie may solicit alternative acquisition proposals.

ZimVie develops and manufactures dental implants and related products for tooth replacement and restoration procedures. ARCHIMED, which manages €8 billion across its funds, focuses exclusively on healthcare investments.

Centerview Partners is serving as financial advisor to ZimVie, while UBS Investment Bank is advising ARCHIMED.

The information in this article is based on a company press release statement. While currently unprofitable, InvestingPro analysts expect ZimVie to return to profitability this year. Discover more insights and 8 additional ProTips about ZimVie in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, ZimVie Inc. reported its first-quarter financial results for 2025, showcasing an impressive performance with earnings per share (EPS) of $0.27, surpassing the projected $0.2216. The company achieved a total revenue of $112 million, which marked a 5.2% decrease from the previous year. Despite the revenue decline, ZimVie demonstrated robust profitability, with a significant 238% increase in adjusted EPS compared to the prior year. Additionally, ZimVie provided optimistic full-year guidance, projecting revenue between $445 million and $460 million.

In a strategic move, ZimVie acquired a distributor in Costa Rica for $3.3 million, aiming to enhance its global distribution network and strengthen its financial position. Analyst firms have shown varied responses to ZimVie’s performance; UBS adjusted its price target for ZimVie shares to $10.00 from $16.00 while maintaining a Neutral rating, citing mixed signals in the company’s recent performance. Meanwhile, Needham reaffirmed its Hold rating on the stock after acknowledging the company’s solid profitability despite revenue shortfalls. Investors will be closely monitoring ZimVie’s performance in light of these recent developments and strategic decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.